Agendia

Agendia company information, Employees & Contact Information

Explore related pages

Related company profiles:

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Company Details

Employees
218
Founded
-
Address
22 Morgan, Irvine,ca 92618,united States
Industry
Biotechnology
HQ
Irvine, CA
Looking for a particular Agendia employee's phone or email?

Agendia Questions

News

Agendia, Inc. Provides Review of Successful 2024 - Business Wire

Agendia, Inc. Provides Review of Successful 2024 Business Wire

Exact's Genomic Health puts rival Agendia in ad watchdog's crosshairs over LinkedIn posts - Fierce Pharma

Exact's Genomic Health puts rival Agendia in ad watchdog's crosshairs over LinkedIn posts Fierce Pharma

National Advertising Division Recommends Agendia Disclose Material Connection to Doctor Featured in Social Media Posts - Yahoo Finance

National Advertising Division Recommends Agendia Disclose Material Connection to Doctor Featured in Social Media Posts Yahoo Finance

Genomic Testing: When Knowledge Gives You the Strength to Keep Fighting - FinancialContent

Genomic Testing: When Knowledge Gives You the Strength to Keep Fighting FinancialContent

I Took Control Of My Health By Learning To Speak Up At The Doctor’s Office - GirlTalkHQ

I Took Control Of My Health By Learning To Speak Up At The Doctor’s Office GirlTalkHQ

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025 - Business Wire

Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025 Business Wire

Agendia Charles Tangu Obituary (2025) - Houston, TX - Unity Funeral Home - Legacy obituary

Agendia Charles Tangu Obituary (2025) - Houston, TX - Unity Funeral Home Legacy obituary

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients - Wiley Online Library

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients Wiley Online Library

Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study - PR Newswire

Agendia® Names Joyce A. O'Shaughnessy, MD as New Principal Investigator for FLEX Study PR Newswire

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care - Illumina

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care Illumina

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines - OncLive

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines OncLive

A Personalized Genetic Test for Breast Cancer Arrives in Europe - Labiotech.eu

A Personalized Genetic Test for Breast Cancer Arrives in Europe Labiotech.eu

ASCO: Agendia test spots ultralow breast cancer recurrence risks, flagging women who could skip chemo - Fierce Biotech

ASCO: Agendia test spots ultralow breast cancer recurrence risks, flagging women who could skip chemo Fierce Biotech

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 20 - Business Wire

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 20 Business Wire

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint® - PR Newswire

New Neoadjuvant Trial Confirms the Predictive Utility of MammaPrint® + BluePrint® PR Newswire

Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024 - BioSpace

Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024 BioSpace

Agendia's FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population - BioSpace

Agendia's FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population BioSpace

MammaPrint® Reimbursement Indication Extended in Belgium - Business Wire

MammaPrint® Reimbursement Indication Extended in Belgium Business Wire

Agendia Again Loses Bid for Breast Cancer Test Medicare Payment - Bloomberg Law News

Agendia Again Loses Bid for Breast Cancer Test Medicare Payment Bloomberg Law News

in Prediction of Extended Endocrine Therapy in Journal of Clinical Oncology - Business Wire

in Prediction of Extended Endocrine Therapy in Journal of Clinical Oncology Business Wire

Agendia and Bluebee Partner to Bring New NGS-based MammaPrint® BluePrint® Breast Cancer Kit to Market - PR Newswire

Agendia and Bluebee Partner to Bring New NGS-based MammaPrint® BluePrint® Breast Cancer Kit to Market PR Newswire

Illumina deal takes Agendia’s tests directly to hospitals - BioCentury

Illumina deal takes Agendia’s tests directly to hospitals BioCentury

AGDX IPO News - Breast cancer diagnostics provider Agendia withdraws $75 million IPO - renaissancecapital.com

AGDX IPO News - Breast cancer diagnostics provider Agendia withdraws $75 million IPO renaissancecapital.com

Agendia, Inc to pay $8.25 million for Medicare false claims; Mercy Health – Lourdes Hospital also settles - KFVS12

Agendia, Inc to pay $8.25 million for Medicare false claims; Mercy Health – Lourdes Hospital also settles KFVS12

Agendia Eyes Commercial Expansion, Collaborations with $35M Financing - Inside Precision Medicine

Agendia Eyes Commercial Expansion, Collaborations with $35M Financing Inside Precision Medicine

Agendia Teams With Ilumina To Transform Breast Cancer Testing Through NGS Advancement - The Healthcare Technology Report.

Agendia Teams With Ilumina To Transform Breast Cancer Testing Through NGS Advancement The Healthcare Technology Report.

Why She's Using A Breast Cancer Flash Mob to Create Awareness: Cari Grundman - HuffPost

Why She's Using A Breast Cancer Flash Mob to Create Awareness: Cari Grundman HuffPost

What's Going Around: flu and pneumonia - KPLC 7 News

What's Going Around: flu and pneumonia KPLC 7 News

Breast cancer tests spawn marketing war - Orange County Register

Breast cancer tests spawn marketing war Orange County Register

How innovative genomic testing is transforming early breast cancer care | User | poteaudailynews.com - FinancialContent

How innovative genomic testing is transforming early breast cancer care | User | poteaudailynews.com FinancialContent

Top Agendia Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant